Follow
Peter Tummino
Peter Tummino
Chief Scientific Officer, Nimbus Therapeutics
Verified email at nimbustx.com
Title
Cited by
Cited by
Year
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
RA Alm, LSL Ling, DT Moir, BL King, ED Brown, PC Doig, DR Smith, ...
Nature 397 (6715), 176-180, 1999
24371999
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
MT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ...
Nature 492 (7427), 108-112, 2012
19052012
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
C Vickers, P Hales, V Kaushik, L Dick, J Gavin, J Tang, K Godbout, ...
Journal of Biological Chemistry 277 (17), 14838-14843, 2002
18772002
Residence time of receptor− ligand complexes and its effect on biological function
PJ Tummino, RA Copeland
Biochemistry 47 (20), 5481-5492, 2008
6132008
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
MT McCabe, AP Graves, G Ganji, E Diaz, WS Halsey, Y Jiang, ...
Proceedings of the National Academy of Sciences 109 (8), 2989-2994, 2012
5422012
A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC
HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ...
Cancer cell 28 (1), 57-69, 2015
5012015
Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin
SD Knight, ND Adams, JL Burgess, AM Chaudhari, MG Darcy, ...
ACS Medicinal Chemistry Letters 1 (1), 39-43, 2010
4082010
Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2
SK Verma, X Tian, LV LaFrance, C Duquenne, DP Suarez, KA Newlander, ...
ACS medicinal chemistry letters 3 (12), 1091-1096, 2012
4052012
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
PK Mazur, N Reynoird, P Khatri, PWTC Jansen, AW Wilkinson, S Liu, ...
Nature 510 (7504), 283-287, 2014
3992014
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R Kumar, MC Crouthamel, DH Rominger, RR Gontarek, PJ Tummino, ...
British journal of cancer 101 (10), 1717-1723, 2009
2462009
Helicobacter pylori Physiology Predicted from Genomic Comparison of Two Strains
P Doig, BL de Jonge, RA Alm, ED Brown, M Uria-Nickelsen, B Noonan, ...
Microbiology and Molecular Biology Reviews 63 (3), 675-707, 1999
2411999
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models
A Wyce, G Ganji, KN Smitheman, C Chung, S Korenchuk, Y Bai, ...
PloS one 8 (8), e72967, 2013
2252013
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
A Chaidos, V Caputo, K Gouvedenou, B Liu, I Marigo, MS Chaudhry, ...
Blood, The Journal of the American Society of Hematology 123 (5), 697-705, 2014
2222014
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors
NA Dales, AE Gould, JA Brown, EF Calderwood, B Guan, CA Minor, ...
Journal of the American Chemical Society 124 (40), 11852-11853, 2002
2192002
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation
GS Van Aller, N Reynoird, O Barbash, M Huddleston, S Liu, AF Zmoos, ...
Epigenetics 7 (4), 340-343, 2012
2072012
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
A Wyce, Y Degenhardt, Y Bai, BC Le, S Korenchuk, MC Crouthamel, ...
Oncotarget 4 (12), 2419, 2013
2032013
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
GS Van Aller, JD Carson, W Tang, H Peng, L Zhao, RA Copeland, ...
Biochemical and biophysical research communications 406 (2), 194-199, 2011
1862011
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
RM Campbell, PJ Tummino
The Journal of clinical investigation 124 (1), 64-69, 2014
1852014
Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a …
DA Heerding, N Rhodes, JD Leber, TJ Clark, RM Keenan, LV Lafrance, ...
Journal of medicinal chemistry 51 (18), 5663-5679, 2008
1752008
Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
JD Carson, G Van Aller, R Lehr, RH Sinnamon, RB Kirkpatrick, KR Auger, ...
Biochemical Journal 409 (2), 519-524, 2008
1532008
The system can't perform the operation now. Try again later.
Articles 1–20